Clene (NASDAQ:CLNN) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

Shares of Clene Inc. (NASDAQ:CLNN – Get Free Report) passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.89 and traded as low as $3.51. Clene shares last traded at $3.66, with a volume of 123,344 shares traded.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CLNN. Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of Clene in a report on Monday, October 19th. Finally, Wall Street Zen upgraded Clene from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Check Out Our Latest Research Report on Clene

Clene Stock Performance

The firm has a market cap of $52.70 million, a PE ratio of -1.41 and a beta of 1.04. The stock’s 50 day simple moving average is $3.89 and its 200 day simple moving average is $5.10.

Clene (NASDAQ:CLNN – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.50. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.07 million. As a group, analysts anticipate that Clene Inc. will post -1.05 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Clene stock. State Street Corp raised its position in shares of Clene Inc. (NASDAQ:CLNN – Free Report) by 27.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,901 shares of the company’s stock after purchasing an additional 8,100 shares during the period. State Street Corp owned approximately 0.26% of Clene worth $155,000 at the end of the most recent reporting period. 23.28% of the stock is owned by institutional investors.

Clene Company Profile

(Get Free Report)

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. Founded in 2013 and based in Salt Lake City, Utah, the company focuses on research and development rather than marketed medicines. Its lead investigational candidate, CNM-Au8, is a suspension of gold nanocrystals designed to support cellular energy production and protect nerve cells. Clene has studied CNM-Au8 in clinical programs for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

Further Reading

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.